Trial Profile
A Randomized, Double-blind, Placebo-controlled, Multicenter, Adaptive Phase III Trial to Investigate Efficacy and Safety of Vilobelimab in the Treatment of Ulcerative Pyoderma Gangrenosum
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 02 May 2024
Price :
$35
*
At a glance
- Drugs Vilobelimab (Primary)
- Indications Pyoderma gangrenosum
- Focus Registrational; Therapeutic Use
- Sponsors InflaRx
- 22 Mar 2024
- 06 Nov 2023 According to an InflaRx media release, first patient has been dosed in USA.
- 01 Nov 2023 According to an InflaRx media release, company has initiated the first six clinical sites in the United States and is actively screening patients.